← Issue №9/ week of Aug 30, 2026/IBD

Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.

From GI Signals issue №9: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD review · Aug 27, 2026 · Inflamm Bowel Dis · IF 4.5

Targeting the TL1A pathway in inflammatory bowel disease: mechanistic insights and emerging therapeutic pipeline.

New therapybiologicsCrohn's diseaseulcerative colitisbasic science
Clinical takeawayNo clinical action yet: phase 3 trials are ongoing, and these therapies are not yet approved for use in IBD.
What it foundPhase 2 trials of anti-TL1A monoclonal antibodies (tulisokibart, afimkibart, duvakitug) achieved clinical remission rates of 26%-48% in ulcerative colitis (placebo-adjusted differences 15-26 percentage points) and endoscopic response rates of 26%-48% in Crohn's disease.
ContextThis review highlights emerging evidence for TL1A inhibitors as a novel therapeutic class targeting both inflammation and fibrosis in IBD, with phase 3 results expected in 2026-2027.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Quraishi MN … Al-Bawardy B · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №9 Every paper GI Signals surfaces gets a page like this one. All issues